mianserin has been researched along with Weight Gain in 25 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this open-label, 8-week study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV major depressive disorder who had failed previous therapy with an SSRI (fluoxetine, paroxetine, or sertraline) were evaluated." | 9.09 | Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. ( Cohen, M; Dunner, DL; Fava, M; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J, 2001) |
| "To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia." | 8.98 | Mirtazapine adjunct for people with schizophrenia. ( Perry, LA; Ramson, D; Stricklin, S, 2018) |
| "Mirtazapine is a relatively new so-called noradrenergic and specific serotonergic antidepressant, which is more specific and therefore generally better tolerated." | 6.71 | Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R, 2004) |
| "Nineteen patients (12 women and 7 men), with SSRI-induced sexual dysfunction who were in remission from major depressive disorder (total Hamilton Rating Scale for Depression [HAM-D] score < or = 10), were switched to open-label mirtazapine for up to 6 weeks." | 5.09 | Mirtazapine substitution in SSRI-induced sexual dysfunction. ( Delgado, P; Gelenberg, AJ; Laukes, C; McGahuey, C; Moreno, F; Okayli, G; Zentner, L, 2000) |
| "In this open-label, 8-week study, the efficacy and safety of mirtazapine among 103 outpatients with DSM-IV major depressive disorder who had failed previous therapy with an SSRI (fluoxetine, paroxetine, or sertraline) were evaluated." | 5.09 | Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. ( Cohen, M; Dunner, DL; Fava, M; Greist, JH; Preskorn, SH; Trivedi, MH; Zajecka, J, 2001) |
| "The aim of this study was to conduct a naturalistic, open-label examination of the efficacy and tolerability of mirtazapine (a medication with both serotonergic and noradrenergic properties) in the treatment of associated symptoms of autism and other pervasive developmental disorders (PDDs)." | 5.09 | A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. ( Guenin, KD; Kohn, AE; McDougle, CJ; Posey, DJ; Swiezy, NB, 2001) |
| "To systematically assess the effects of mirtazapine as adjunct treatment for people with schizophrenia." | 4.98 | Mirtazapine adjunct for people with schizophrenia. ( Perry, LA; Ramson, D; Stricklin, S, 2018) |
| "Mirtazapine is a relatively new so-called noradrenergic and specific serotonergic antidepressant, which is more specific and therefore generally better tolerated." | 2.71 | Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache. ( Bendtsen, L; Jensen, R, 2004) |
| "Mirtazapine is a novel antidepressant which has a mechanism that involves the enhancement of noradrenergic and serotonergic neurotransmission via blockade of alpha2-adrenergic autoreceptors and heteroreceptors without activity at the serotonin transporter." | 2.69 | Mirtazapine augmentation in the treatment of refractory depression. ( Carpenter, LL; Hall, JM; Jocic, Z; Price, LH; Rasmussen, SA, 1999) |
| "Anecdotal reports have suggested that the long-term use of selective serotonin reuptake inhibitors (SSRIs) may be associated with significant weight gain, sexual dysfunction, drug interactions, and discontinuation symptoms." | 2.41 | Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine. ( Gupta, S; Masand, PS, 2002) |
| "Mirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety." | 2.40 | Mirtazapine: clinical advantages in the treatment of depression. ( Burrows, GD; Kremer, CM, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 16 (64.00) | 29.6817 |
| 2010's | 6 (24.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Perry, LA | 1 |
| Ramson, D | 1 |
| Stricklin, S | 1 |
| Song, HR | 1 |
| Kwon, YJ | 1 |
| Woo, YS | 2 |
| Bahk, WM | 2 |
| Seo, HJ | 1 |
| Jung, YE | 1 |
| Jun, TY | 1 |
| Chae, JH | 1 |
| Lee, HY | 1 |
| Kang, RH | 1 |
| Paik, JW | 1 |
| Jeong, YJ | 1 |
| Chang, HS | 1 |
| Han, SW | 1 |
| Lee, MS | 1 |
| Laika, B | 1 |
| Leucht, S | 1 |
| Heres, S | 1 |
| Schneider, H | 1 |
| Steimer, W | 1 |
| Risselada, AJ | 1 |
| Mulder, H | 1 |
| Heerdink, ER | 1 |
| Grube, AM | 1 |
| Wilmink, FW | 1 |
| Egberts, TC | 1 |
| Chiu, HW | 1 |
| Li, TC | 1 |
| Schilling, C | 1 |
| Gilles, M | 1 |
| Blum, WF | 1 |
| Daseking, E | 1 |
| Colla, M | 1 |
| Weber-Hamann, B | 1 |
| Lederbogen, F | 1 |
| Krumm, B | 1 |
| Heuser, I | 1 |
| Wudy, SA | 1 |
| Kopf, D | 1 |
| Deuschle, M | 1 |
| Goldberg, RJ | 1 |
| Abraham, G | 1 |
| Masand, PS | 1 |
| Gupta, S | 1 |
| Gupta, RK | 1 |
| Tiller, JW | 1 |
| Burrows, GD | 2 |
| Fisfalen, ME | 1 |
| Hsiung, RC | 1 |
| Bendtsen, L | 1 |
| Jensen, R | 1 |
| Pallanti, S | 1 |
| Quercioli, L | 1 |
| Bruscoli, M | 1 |
| Silva, AL | 1 |
| Cabral, AM | 1 |
| Abreu, GR | 1 |
| Pires, JG | 1 |
| Bissoli, NS | 1 |
| Ramage, AG | 1 |
| Gambi, F | 1 |
| De Berardis, D | 1 |
| Campanella, D | 1 |
| Carano, A | 1 |
| Sepede, G | 1 |
| Salini, G | 1 |
| Mezzano, D | 1 |
| Cicconetti, A | 1 |
| Penna, L | 1 |
| Salerno, RM | 1 |
| Ferro, FM | 1 |
| Himmerich, H | 1 |
| Fulda, S | 1 |
| Schaaf, L | 1 |
| Beitinger, PA | 1 |
| Schuld, A | 1 |
| Pollmächer, T | 1 |
| Hannan, N | 1 |
| Hamzah, Z | 1 |
| Akinpeloye, HO | 1 |
| Meagher, D | 1 |
| Kremer, CM | 1 |
| Carpenter, LL | 2 |
| Jocic, Z | 1 |
| Hall, JM | 1 |
| Rasmussen, SA | 1 |
| Price, LH | 2 |
| Leon, Z | 1 |
| Yasmin, S | 1 |
| Gelenberg, AJ | 1 |
| McGahuey, C | 1 |
| Laukes, C | 1 |
| Okayli, G | 1 |
| Moreno, F | 1 |
| Zentner, L | 1 |
| Delgado, P | 1 |
| Fava, M | 1 |
| Dunner, DL | 1 |
| Greist, JH | 1 |
| Preskorn, SH | 1 |
| Trivedi, MH | 1 |
| Zajecka, J | 1 |
| Cohen, M | 1 |
| Posey, DJ | 1 |
| Guenin, KD | 1 |
| Kohn, AE | 1 |
| Swiezy, NB | 1 |
| McDougle, CJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypothalamus-pituitary-adrenal System: Role of the Mineralocorticoid Receptor and Longitudinal Study in Depressed Patients[NCT01049347] | Phase 3 | 127 participants (Actual) | Interventional | 1997-10-31 | Completed | ||
| The Effects of a High Eicosapentaenoic Acid Multinutrient Supplement on Measures of Stress, Anxiety and Depression in Young Adults: a Randomised, Double-blind, Placebo-controlled Trial.[NCT04844034] | 94 participants (Anticipated) | Interventional | 2022-04-19 | Recruiting | |||
| Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause[NCT03740009] | Phase 4 | 20 participants (Actual) | Interventional | 2019-01-02 | Completed | ||
| Efficacy and Safety Analyses of Mirtazapine in the Treatment of Malignant Tumor Related Depression: A Phase II, Placebo-controlled, Randomized, Double-blinded Clinical Trial in Advanced Non-small Cell Lung Cancer Patients[NCT02650544] | Phase 2 | 236 participants (Anticipated) | Interventional | 2015-12-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The primary outcome measure is functional magnetic resonance imaging (fMRI) data collected during a Monetary Incentive Delay (MID) Task. All participants will complete the fMRI Monetary Incentive Delay (MID) task at baseline and at 3 weeks. During the task, participants need to select the correct response during win and lose conditions by pressing a button on a button box in the MRI. Participant's blood-oxygen-level dependent (BOLD) activation response (A measurement of oxygen level that is released to neurons since areas of the brain that are thought to be more active or involved in certain tasks require more oxygen to perform the tasks.) is measured while they performed the task in MRI scanner." (NCT03740009)
Timeframe: Baseline to 3 weeks
| Intervention | percent signal change (Mean) | |||||
|---|---|---|---|---|---|---|
| Caudate Baseline | Caudate Posttreatment | Nucleus Accumbens Baseline | Nucleus Accumbens Posttreatment | Putamen Baseline | Putamen Posttreatment | |
| Perimenopausal Women, Depressed | .0704 | .0475 | .0623 | .0280 | .0399 | .0408 |
The second primary outcome measure uses the Mood and Anxiety Symptoms Questionnaire - Anhedonic Depression Scale (MASQ-AD) to examine symptom change. All participants will complete the MASQ-AD at each study visit, which measures their current symptoms of depression and anxiety. Scores range from 22 to 110 with lower scores reflecting a better outcome. (NCT03740009)
Timeframe: Baseline, week 2, week 3, week 4 (post treatment)
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline Week 1 | Week 2 | Week 3 | Post Treatment Week 4 | |
| Perimenopausal Women, Depressed | 72.1 | 62.4 | 57.2 | 54.5 |
4 reviews available for mianserin and Weight Gain
| Article | Year |
|---|---|
Mirtazapine adjunct for people with schizophrenia.
Topics: Antidepressive Agents, Tricyclic; Antipsychotic Agents; Chemotherapy, Adjuvant; Humans; Mianserin; M | 2018 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Long-term side effects of newer-generation antidepressants: SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Drug Interactions; Humans; Mians | 2002 |
Dual action antidepressants and some important considerations.
Topics: Adrenergic alpha-Antagonists; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes | 2003 |
Mirtazapine: clinical advantages in the treatment of depression.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Clinical Trials as Topic; Clomipramine | 1997 |
10 trials available for mianserin and Weight Gain
| Article | Year |
|---|---|
Effect of augmented atypical antipsychotics on weight change in patients with major depressive disorder in a naturalistic setting.
Topics: Adult; Aged; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Cyclohexanols; Depressive | 2009 |
Leptin plasma concentrations increase during antidepressant treatment with amitriptyline and mirtazapine, but not paroxetine and venlafaxine: leptin resistance mediated by antihistaminergic activity?
Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Biomarke | 2013 |
Mirtazapine is effective in the prophylactic treatment of chronic tension-type headache.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Adult; Area Under Curve; Chro | 2004 |
Response acceleration with mirtazapine augmentation of citalopram in obsessive-compulsive disorder patients without comorbid depression: a pilot study.
Topics: Adult; Age of Onset; Antidepressive Agents, Tricyclic; Citalopram; Comorbidity; Depressive Disorder; | 2004 |
Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study.
Topics: Adult; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Constipation; Female; Humans; | 2005 |
Mirtazapine augmentation in the treatment of refractory depression.
Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depres | 1999 |
Clinical experience with mirtazapine in the treatment of panic disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Drug Administration | 1999 |
Mirtazapine substitution in SSRI-induced sexual dysfunction.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Depressive Disorder; Female; Humans; Irritable Mood; Male | 2000 |
Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Tricyclic; Depressive Disorder; Double-Blind Method; | 2001 |
A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders.
Topics: Adolescent; Adult; Aggression; Antidepressive Agents, Tricyclic; Anxiety Disorders; Appetite; Autist | 2001 |
11 other studies available for mianserin and Weight Gain
| Article | Year |
|---|---|
Effects of Mirtazapine on Patients Undergoing Naturalistic Diabetes Treatment: A Follow-Up Study Extended From 6 to 12 Months.
Topics: Adult; Antidepressive Agents, Tricyclic; Diabetes Mellitus; Follow-Up Studies; Humans; Mianserin; Mi | 2015 |
Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder.
Topics: Adrenergic alpha-Antagonists; Adult; Depressive Disorder, Major; Female; Genetic Predisposition to D | 2009 |
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome.
Topics: Adult; Aged; Benzodiazepines; Cytochrome P-450 CYP1A2; Depressive Disorder; Female; Genotype; Humans | 2010 |
The association between serotonin 2C receptor polymorphisms and weight gain and eating behavior in patients using mirtazapine: a prospective follow-up study.
Topics: Adult; Aged; Feeding Behavior; Female; Follow-Up Studies; Haplotypes; Humans; Male; Mianserin; Middl | 2010 |
Rapid weight gain during mirtazapine treatment.
Topics: Humans; Male; Mianserin; Mirtazapine; Time Factors; Treatment Outcome; Weight Gain; Young Adult | 2011 |
Weight change in depressed nursing home patients on mirtazapine.
Topics: Aged; Antidepressive Agents, Tricyclic; Depression; Female; Homes for the Aged; Humans; Male; Mianse | 2002 |
Massive weight gain and hostility force mirtazapine stoppage.
Topics: Adult; Affect; Antidepressive Agents, Tricyclic; Depressive Disorder; Female; Hostility; Humans; Mia | 2002 |
Glucose dysregulation and mirtazapine-induced weight gain.
Topics: Adult; Antidepressive Agents, Tricyclic; Blood Glucose; Body Mass Index; Cocaine-Related Disorders; | 2003 |
Chronic treatment with mianserin prevents DOCA-salt hypertension in rats--evidence for the involvement of central 5-HT2 receptors.
Topics: Animals; Blood Pressure; Desoxycorticosterone; Dose-Response Relationship, Drug; Drinking; Heart Rat | 2005 |
Changes in weight and glucose tolerance during treatment with mirtazapine.
Topics: Antidepressive Agents, Tricyclic; Blood Glucose; Body Weight; Depressive Disorder; Female; Glucose T | 2006 |
Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cyclohexano | 2007 |